Crispr (CRSP) Stock
Fundamentals
Recent news

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRSP

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRSP

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP

CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRSP
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.12 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRSP

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRSP

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP

CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRSP

3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
CRSP

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
CRSP

Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
CRSP

Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Is a Good Investment: Is It?
CRSP

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRSP

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRSP
About Crispr
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman | 1978 |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer | 1984 |
| Mr. James R. Kasinger J.D. | General Counsel & Secretary | 1972 |
| Dr. Naimish Patel C.M., M.D. | Chief Medical Officer | 1972 |
| Mr. Shaun Foy CFA | Co-Founder | — |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member | — |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | — |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | 1972 |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 1965 |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member | 1970 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
4 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.6 | -17.9 | -16.3 | +0.7 | ||||||||
| 2022 | -19.5 | -6.3 | +9.3 | -25.0 | +11.7 | +5.0 | +17.6 | -12.1 | -0.4 | -17.1 | +5.3 | -25.2 |
| 2023 | +24.4 | -5.8 | -5.2 | +8.1 | +30.5 | -13.0 | +1.9 | -11.3 | -10.2 | -8.2 | +52.5 | -8.8 |
| 2024 | -4.7 | +30.2 | -18.6 | -22.3 | -0.1 | -5.5 | +6.2 | -13.0 | +3.2 | +1.8 | +0.8 | -28.6 |
| 2025 | +0.4 | +9.8 | -19.5 | +16.7 | -3.8 | +31.6 | +16.0 | -7.6 | +23.1 | -3.3 | -13.7 | +0.5 |
| 2026 | -7.1 | +17.2 | -21.7 | +7.2 | +8.8 | +0.6 | -13.7 | +14.9 | -4.6 |



